Niclosamide as a Promising Therapeutic Player in Human Cancer and Other Diseases

Int J Mol Sci. 2022 Dec 17;23(24):16116. doi: 10.3390/ijms232416116.

Abstract

Niclosamide is an FDA-approved anthelmintic drug for the treatment of parasitic infections. However, over the past few years, increasing evidence has shown that niclosamide could treat diseases beyond parasitic diseases, which include metabolic diseases, immune system diseases, bacterial and viral infections, asthma, arterial constriction, myopia, and cancer. Therefore, we systematically reviewed the pharmacological activities and therapeutic prospects of niclosamide in human disease and cancer and summarized the related molecular mechanisms and signaling pathways, indicating that niclosamide is a promising therapeutic player in various human diseases, including cancer.

Keywords: FDA-approved drug; cancer; disease; niclosamide; pharmacological activity; therapeutic prospect.

Publication types

  • Systematic Review
  • Review

MeSH terms

  • Anthelmintics* / pharmacology
  • Anthelmintics* / therapeutic use
  • Humans
  • Neoplasms* / drug therapy
  • Niclosamide / pharmacology
  • Niclosamide / therapeutic use
  • Signal Transduction
  • Vascular Diseases* / drug therapy

Substances

  • Niclosamide
  • Anthelmintics